Close Menu

NEW YORK – Ubiquitome said on Monday that it has signed an exclusive agreement with Switzerland-based market expansion services group DiethelmKellerSiberHegner (DKSH) to market and sell Ubiquitome's mobile PCR-based COVID-19 testing platform Liberty16 in several countries in the Asia-Pacific region.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.